Yue-Fan Wang, Wen-Li Zhang, Zhi-Xuan Li, Yue Liu, Jian Tan, Hao-Zan Yin, Zhi-Chao Zhang, Xian-Jie Piao, Min-Hao Ruan, Zhi-Hui Dai, Si-Jie Wang, Chen-Yang Mu, Ji-Hang Yuan, Shu-Han Sun, Hui Liu, Fu Yang
Without intervention, a considerable proportion of patients with metabolism-associated fatty liver disease (MAFLD) will progress from simple steatosis to metabolism-associated steatohepatitis (MASH), liver fibrosis, and even hepatocellular carcinoma. However, the molecular mechanisms that control progressive MAFLD have yet to be fully determined. Here, we unraveled that the expression of the N6-methyladenosine (m6A) methyltransferase METTL14 is remarkably downregulated in the livers of both patients and several murine models of MAFLD, whereas hepatocyte-specific depletion of this methyltransferase aggravated lipid accumulation, liver injury, and fibrosis...
April 17, 2024: Signal Transduction and Targeted Therapy